Laura Réjane Lucie Flore Leroy

Ms. Laura Réjane Lucie Flore Leroy

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Lucie DarmuseyLucie Darmusey
Lucie Darmusey
GPGaelle Perot
Gaelle Perot
NTNoémie Thébault
Noémie Thébault
SGSophie Le Guellec
Sophie Le Guellec
NDNelly Desplat
Nelly Desplat
Frédéric ChibonFrédéric Chibon
Frédéric Chibon
Whole genome and transcriptome sequencing of a cohort of 67 leiomyosarcomas has been revealed ATRX to be one of the most frequently mutated genes in leiomyosarcomas after TP53 and RB1. While its function is well described in the alternative lengthening of telomeres mechanism, we wondered whether its alteration could have complementary effects on sarcoma oncogenesis. ATRX alteration is associated with the down-expression of genes linked to differentiation in leiomyosarcomas, and to immunity in an additional cohort of 60 poorly differentiated pleomorphic sarcomas. In vitro and in vivo models showed that ATRX down-expression increases tumor growth rate and immune escape by decreasing the immunity load of active mast cells in sarcoma tumors. These data indicate that an alternative to unsuccessful targeting of the adaptive immune system in sarcoma could target the innate system. This might lead to a better outcome for sarcoma patients in terms of ATRX status.

15 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EDelodie darbo
elodie darbo
GPGaelle Perot
Gaelle Perot
LDLucie Darmusey
Lucie Darmusey
SGSophie Le Guellec
Sophie Le Guellec
LLLaura Réjane Lucie Flore Leroy
Laura Réjane Lucie Flore Leroy
Frédéric ChibonFrédéric Chibon
Frédéric Chibon
In leiomyosarcoma (LMS), a very aggressive disease, a relatively transcriptionally uniform subgroup of well-differentiated tumors has been described and is associated with poor survival. The question raised how differentiation and tumor progression, two apparently antagonist processes, coexist and allow tumor malignancy. We first identified the most transcriptionally homogeneous LMS subgroup in three independent cohorts, which we named ‘hLMS’. The integration of multi-omics data and functional analysis suggests that hLMS originate from vascular smooth muscle cells and show that hLMS transcriptional program reflects both modulations of smooth muscle contraction activity controlled by MYOCD/SRF regulatory network and activation of the cell cycle activity controlled by E2F/RB1 pathway. We propose that the phenotypic plasticity of vascular smooth muscle cells coupled with MYOCD/SRF pathway amplification, essential for hLMS survival, concomitant with PTEN absence and RB1 alteration, could explain how hLMS balance this uncommon interplay between differentiation and aggressiveness.